Palobiofarma S.L. Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome

Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10 (PDE-10) inhibitor, PBF-999, for the treatment of patients with Prader-Willi Syndrome (PWS). “Pediatric patients living with PWS suffer from hyperphagia, a significant unmet need with very limited treatment options,” said Julio Castro, PhD, Chief Executive Officer of Palobiofarma S.L. “Obtaining Rare Pediatric Disease Designation from the FDA is an outstanding achievement for a small Spanish Biotech company and supports our mission to provide PBF-999 as a potential new treatment option for patients suffering from PWS.” About Rare Pediatric Disease Designation Rare Pediatric Disease (RPD) Designation is granted by the FDA for serious or life-threatening diseases which affect fewer than 200,000 people in the United States and in which the serious or life-threatening manifestations primarily affect individuals less than 18 years of age. If a New Drug Application (NDA) for PBF-999 for the treatment of PWS is approved by the FDA, Palobiofarma S.L. may be eligible to receive a Priority Review Voucher (PRV) that can be redeemed to receive a priority review for any subsequent marketing application. This program is intended to encourage the development of new drugs and biologics for the treatment of rare pediatric diseases. About Prader-Willi Syndrome Prader-Willi syndrome (PWS) is a variable and complex genetic neurobehavioral disorder resulting from abnormality on the 15th chromosome. It occurs in males and females equally and in all races. Prevalence estimates range from 1:15,000 to 1:25,000 (approximately 400 000 to 530 000 affected people worldwide). The most common and challenging symptom among those diagnosed is hyperphagia, an intense, insatiable hunger characterized by a constant desire to eat. Individuals experiencing hyperphagia may engage in continuous eating, leading to life-threatening obesity. There is currently no pharmacological treatment for hyperphagia. About PBF-999 PBF-999 is a novel, potent and selective PDE-10 inhibitor discovered and patented by Palobiofarma. PBF-999 is in Phase 2 clinical development for the treatment of Prader-Willi Syndrome (PWS). About Palobiofarma S.L. Palobiofarma S.L., Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics based on the modulation of the adenosinergic pathways. Palobiofarma exhibits one of the more robust and diversified pipeline of the Biotech sector worldwide, with six different compounds in clinical development targeting diseases of high unmet medical need and is financially supported by well known Spanish VCs like Inveready and Sodena. For more information, please visit www.palobiofarma.com. Share this : Previous Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team Next Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome Related News 0 12 March, 2025 Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 28 August, 2025 Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 30 September, 2019 XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 7 September, 2020 Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting. Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 29 October, 2025 Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 4 March, 2024 PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 12 February, 2024 Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 8 June, 2020 June 8th, 2020: Palobiofarma joins the fight against the Covid-19 pandemia Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 1 January, 2020 oembed Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments 0 3 September, 2020 Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients. Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug... No Comments Recent News Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi SyndromeNo Comments Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi SyndromeNo Comments Archive May 2026 October 2025 August 2025 March 2025 September 2024 April 2024 March 2024 February 2024 November 2023 May 2023 December 2021 November 2021 September 2021 September 2020 June 2020 January 2020 September 2019 January 2019 October 2018 September 2018 March 2018 February 2018 January 2018 Recent Posts Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD. Recent Comments OLanepab on Palobiofarma initiates clinical development of it´s novel dual PDE10/A2a antagonist in solid tumors Anh Keck on Palobiofarma achieves “first patient first visit” in two key Phase II studies i2jdyyugatgffzlqbnuvdipuaxvdblnugyig4ra4ohmfawen3Hca.cdn.ampproject.org on FDA grants Palobiofarma approval to start second anti-cancer study in USA Madeline Dangelo on Palobiofarma achieves “first patient first visit” in two key Phase II studies FobertMem on Palobiofarma initiates clinical development of it´s novel dual PDE10/A2a antagonist in solid tumors Categories News & Events Sin categoría Meta Log in Entries feed Comments feed WordPress.org Privacity Policity | Cookies Policity | Legal Notice PYME INNOVADORA Válido hasta el 21 de octubre de 2025 Copyright © 2019 Palobiofarma. All Rights Reserved. | Web by Arcointeractiva Manage Consent Cookies are important for you, they influence your browsing experience, they help us to protect your privacy and allow us to proceed with your requests that you demand through the website. We use our own and third-party cookies to analyze our services and provide you with advertising related to your preferences on the basis of a profile made with your browsing habits (for example, visited pages). You can "Accept" or "Reject" those cookies that are not technical, as well as configure your preferences by pressing "Cookie settings". For more information, please see our Cookie Policy Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent

The release as fetched from its publisher. palobiofarma.com ↗